Clovis Oncology (NASDAQ:CLVS – Get Rating) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 33,160,000 shares, a growth of 14.4% from the August 31st total of 28,990,000 shares. Based on an average daily volume of 8,440,000 shares, the short-interest ratio is currently 3.9 days.

Hedge Funds Weigh In On Clovis Oncology

Large investors have recently bought and sold shares of the company. First Republic Investment Management Inc. bought a new position in Clovis Oncology in the first quarter valued at about $27,000. Mirabella Financial Services LLP acquired a new stake in shares of Clovis Oncology in the first quarter valued at about $36,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Clovis Oncology in the first quarter valued at about $40,000. Objective Capital Management LLC acquired a new stake in shares of Clovis Oncology in the second quarter valued at about $44,000. Finally, Bank of Montreal Can acquired a new stake in Clovis Oncology during the first quarter worth approximately $48,000. 29.47% of the stock is currently owned by institutional investors.

Clovis Oncology Trading Down 0.4 %

NASDAQ CLVS traded down $0.01 during trading on Tuesday, hitting $1.21. The stock had a trading volume of 8,464 shares, compared to its average volume of 4,165,091. Clovis Oncology has a 12 month low of $0.58 and a 12 month high of $4.76. The company's 50-day moving average price is $1.33 and its two-hundred day moving average price is $1.53.

Clovis Oncology Company Profile

(Get Rating)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

See Also

• Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
• 3 Safe Earnings Plays for a Risk-Off Market
• Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
• Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
• 3 Stocks Growing Their Businesses for 2023
• China-Based EV Maker BYD Set For Big European, Japanese Expansion

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.